Midodrine for the Treatment of Refractory Hypotension

Completed · Phase 3 · Has a placebo group

Conditions studied: Hypotension, Critical Illness

In brief

We hypothesize that midodrine treatment of refractory hypotension in patients otherwise ready for discharge from the ICU shortens duration of receiving IV vasopressors and SICU length of stay without increasing MGH length of stay or putting the patient at risk of being readmitted to an ICU.

Key facts

Study ID

NCT01531959

Run by

Massachusetts General Hospital

People needed

139

Starts

2012-04-01

Expected to finish

2019-06-01

Last updated by the study team

2020-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age
• Admitted to the SICU
• Requiring IV vasopressors at a rate of less than 100 mcg/min of phenylephrine, or 8 mcg/min of norepinephrine, or 60 mcg/min of metaraminol; and unable to wean for more than 24 hours while still maintaining desired blood pressure goal

You may not qualify if…

• Inadequate tissue oxygenation
• Liver failure
• Renal failure
• Hypovolemic shock or hypotension due to adrenal insufficiency
• Pregnancy
• Severe organic heart disease
• Urinary retention
• Pheochromocytoma
• Thyrotoxicosis
• Midodrine as pre-admission medication
• Any known allergies to midodrine
• Enrollment in another clinical trial

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Sir Charles Gairdner Hospital — Nedlands, Western Australia, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.